Brigatinib (23) is an ALK inhibitor, carrying an unusual dimethylphosphine oxide moiety as an H-bond acceptor [106]; it is approved to treat ALK-positive metastatic NSCLC characterized by the presence of an EMAP Like 4 (EML4)−ALK fusion protein. Here, ALK is linked to non-small cell lung carcinoma.